Comprehensive analysis of RNA binding motif protein 3 (RBM3) in non-small cell lung cancer.
biomarker
gene expression
immunohistochemistry
survival
tissue microarray
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
02
01
2020
revised:
11
04
2020
accepted:
05
05
2020
pubmed:
4
6
2020
medline:
3
6
2021
entrez:
4
6
2020
Statut:
ppublish
Résumé
High expression of the RNA-binding motif protein 3 (RBM3) correlates with improved prognosis in several major types of cancer. The aim of the present study was to examine the prognostic value of RBM3 protein and mRNA expression in non-small cell lung cancer (NSCLC). Immunohistochemical expression of RBM3 was evaluated in surgically treated NSCLC from two independent patient populations (n = 213 and n = 306). Staining patterns were correlated with clinicopathological parameters, overall survival (OS), and recurrence-free interval (RFI). Cases with high nuclear RBM3 protein expression had a prolonged 5-year OS in both cohorts when analyzing adenocarcinomas separately (P = .02 and P = .01). RBM3 remained an independent prognostic factor for OS in multivariable analysis of cohort I (HR 0.44, 95% CI 0.21-0.90) and for RFI in cohort II (HR 0.38, 95% CI 0.22-0.74). In squamous cell carcinoma, there was instead an insignificant association to poor prognosis. Also, the expression levels of RBM3 mRNA were investigated in 2087 lung adenocarcinomas and 899 squamous cell carcinomas assembled from 13 and 8 public gene expression microarray datasets, respectively. The RBM3 mRNA levels were not clearly associated with patient outcome in either adenocarcinomas or squamous cell carcinomas. The results from this study support that high protein expression of RBM3 is linked to improved outcome in lung adenocarcinoma.
Identifiants
pubmed: 32491279
doi: 10.1002/cam4.3149
pmc: PMC7402820
doi:
Substances chimiques
RBM3 protein, human
0
RNA-Binding Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5609-5619Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Eur J Cancer. 2014 Mar;50(4):852-61
pubmed: 24380696
Cochrane Database Syst Rev. 2015 Mar 02;(3):CD011430
pubmed: 25730344
Proteomics Clin Appl. 2011 Dec;5(11-12):624-35
pubmed: 21956899
Appl Immunohistochem Mol Morphol. 2016 Oct;24(9):648-659
pubmed: 26447895
Mod Pathol. 2009 Dec;22(12):1564-74
pubmed: 19734850
Biomark Res. 2014 Jun 17;2:11
pubmed: 24963396
PLoS One. 2015 Mar 26;10(3):e0121300
pubmed: 25811459
Nat Med. 2002 Aug;8(8):816-24
pubmed: 12118244
J Transl Med. 2011 Jul 21;9:114
pubmed: 21777469
Oncogene. 2009 Aug 6;28(31):2773-83
pubmed: 19525976
Diagn Pathol. 2011 Sep 28;6:91
pubmed: 21955582
Biomark Res. 2017 Mar 14;5:10
pubmed: 28293425
J Clin Oncol. 2009 Jun 10;27(17):2793-9
pubmed: 19414676
Lung Cancer. 2019 Apr;130:50-58
pubmed: 30885352
PLoS One. 2017 Aug 11;12(8):e0182512
pubmed: 28800641
Cancer Med. 2020 Aug;9(15):5609-5619
pubmed: 32491279
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Oncotarget. 2017 Dec 15;9(5):6188-6200
pubmed: 29464064
Mol Cancer Res. 2013 Jun;11(6):638-50
pubmed: 23449933
Nat Med. 2008 Aug;14(8):822-7
pubmed: 18641660
Clin Cancer Res. 2012 Oct 15;18(20):5606-16
pubmed: 22914773
Nature. 2006 Jan 19;439(7074):353-7
pubmed: 16273092
Diagn Pathol. 2012 Jul 17;7:82
pubmed: 22805320
Cancer Res. 2012 Jan 1;72(1):100-11
pubmed: 22080568
Histopathology. 2016 Jan;68(2):191-8
pubmed: 25922889
J Thorac Oncol. 2014 Jan;9(1):59-64
pubmed: 24305008
PLoS One. 2010 Apr 22;5(4):e10312
pubmed: 20421987
BMC Urol. 2013 Apr 08;13:17
pubmed: 23565664
J Thorac Oncol. 2016 Jun;11(6):862-72
pubmed: 26872818
Cancer Res. 2006 Aug 1;66(15):7466-72
pubmed: 16885343
JCI Insight. 2016 Jul 7;1(10):e86837
pubmed: 27699219
J Cancer Res Clin Oncol. 2019 Apr;145(4):873-879
pubmed: 30758670
Clin Cancer Res. 2013 Sep 15;19(18):5116-26
pubmed: 23938291
Clin Cancer Res. 2008 Nov 15;14(22):7397-404
pubmed: 19010856
J Transl Med. 2010 Aug 20;8:78
pubmed: 20727170
Sci Transl Med. 2013 Oct 30;5(209):209ra153
pubmed: 24174329
Br J Cancer. 2014 Sep 9;111(6):1222-9
pubmed: 25051406
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
Am J Clin Pathol. 2013 Jul;140(1):37-46
pubmed: 23765532
Oncotarget. 2017 Mar 28;8(13):22235-22250
pubmed: 28118608